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Abstract
Background: Although Philadelphia-negative myeloproliferative neoplasms (Ph-MPN) are usually not aggressive,
the type and the number of molecular lesions impact greatly on leukemic transformation. Indeed, the molecular
background underlying progression is still largely unexplored even though ASXL1, IDH1/2, SRSF2, and TP53 mutations,
together with adverse karyotypic changes, place the patient at high risk of leukemic transformation.
Case presentation: Our patient, a 64-year old man with a diagnosis of JAK2V617F primary myelofibrosis (PMF) had an
unusually rapid leukemic transformation. Genomic profiling showed that TET2 and SRSF2 mutations were also present.
At leukemic transformation, the patient developed a complex chromosome rearrangement producing a EWSR1-MYB
fusion. Remarkably, the expression of MYB and of its target BCL2 was, respectively, ≥4.7 and ≥2.8 fold higher at
leukemic transformation than after chemotherapy, when the patient obtained the hematological remission. At
this time point, the EWSR1-MYB fusion disappeared while JAK2V617F, TET2, and SRSF2 mutations, as well as PMF
morphological features persisted.
Conclusions: Rapid leukemic transformation of JAK2V617F PMF was closely linked to a previously undescribed
putative EWSR1-MYB transcription factor which was detected only at disease evolution. We hypothesize that the
EWSR1-MYB contributed to leukemia transformation through at least two mechanisms: 1) it sustained MYB expression,
and consequently deregulated its target BCL2, a putative onco-suppressor gene; and 2) ectopic EWSR1-MYB expression
probably fulfilled its own oncogenic potential as demonstrated for other MYB-fusions. As our study confirmed that MYB
is recurrently involved in chronic as well as leukemic transformation of PMF, it appears to be a valid molecular marker
for tailored treatments.
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Background
Ph-MPN are usually not aggressive malignancies. Evolu-
tion into Acute Myeloid Leukemia (AML) occurs in
~2 % of Polycythemia Vera (PV), 1 % of Essential
Thrombocytopenia (ET), and 10–20 % of PMF, consider-
ing the first decade of disease. Although, transformation
rates increase with genotoxic therapy, leukemic trans-
formation is part of the natural history of these disorders
as AML also occurs in treatment-naive patients [1, 2].
Genomic profiling of Ph-MPN is useful for under-
standing the pathobiology of leukemic transformation
and improving prognostic stratification of patients and
treatment. During leukemic transformation very few
new mutations are acquired and the majority of somatic
mutations are already present in the chronic phase. Two
or more mutations affecting ASXL1, IDH1/2, SRSF2, and
TP53, are considered high-risk events. Besides muta-
tions, unfavourable (chromosome 3, 5 or 7 rearrange-
ments), and very unfavourable (chromosome 17
abnormalities) karyotypic changes impact upon progno-
sis [3, 4]. In any case, the molecular mechanisms under-
lying the progression from Ph-MPN to AML are not yet
completely understood [5–9].
Longitudinal genomic investigation into a unique case
of JAK2V617F positive PMF with rapid leukemic evolution,
detected a leukemia-specific complex rearrangement in-
volving chromosomes 6, 9 and 22 which produced an ab-
errant EWSR1-MYB transcription factor. EWSR1-MYB
ectopic expression, as well as high expression of MYB and
its target BCL2, likely contributed to the leukemia
phenotype. It is worth mentioning that, high level of
MYB expression blocks differentiation and confers self-
renewal properties to leukemic cells, whereas the ex-
pression of the anti-apoptotic BCL2 protein inhibits
leukemic cell death [10–12].
Case presentation
In January 2011, a 64-year-old man was referred to our
Department with leukocytosis (WBC 20.100/uL with
71.8 % neutrophils), macrocytic anemia (Hb 11,5 g/dL;
MCV 104 fl), splenomegaly, and hepatomegaly. Bone mar-
row (BM) biopsy revealed PMF with grade 1 fibrosis;
karyotype was normal. The JAK2V617F mutation was found
at 60 % allelic burden. After 4 months the patient devel-
oped an acute myeloid leukemia (AML; M2 morphology)
and acquired an ins(6;22)(q23.3;q11) in the 20 meta-
phases analyzed (Fig. 1a). He was treated according to
the FLAI protocol [13] and obtained hematologic and
cytogenetic remission. Myeloproliferative features, in-
cluding JAK2V617F, persisted. Demethylating treatment
with 5-azacytidine (5-AZA) was administered for 8 cy-
cles, reducing anemia and splenomegaly, but treatment
was discontinued because the patient developed a
gastric adenocarcinoma. He died 30 months after PMF
was diagnosed.
Methods
Molecular-cytogenetic and mutational analyses
All molecular and cytogenetic studies were carried out on
BM samples. Multi-FISH (24XCyte Multi-colour probe kit,
MetaSystems), whole chromosome paints for chromosomes
6, 9 and 22 (Cytocell, Milan, Italy), and metaphase FISH with
DNA clones for MYB (G248P8686G9 and G248P89100B2),
EWSR1 (G248P89991F7 and G248P80286D12), 9q33.1-
q33.3, and 22q11-q12 regions, were done at leukemic trans-
formation (Additional file 1 and Additional file 2: Tables S1,
S2, S3). A EWSR1-MYB FISH assay (RP1-32B1 for MYB
and RP11-367E7 for EWSR1) was performed at leukemic
transformation, diagnosis and post-chemotherapy. The
EWSR1-MYB assay was also applied to a cohort of 7 PMF
and 3 leukemia groups (Additional file 1). Single Nucleo-
tide Polymorphism array (SNPa) experiments were per-
formed at initial PMF and at leukemic transformation;
targeted mutational analysis of DNMT3A, SETBP1, EZH2,
IDH1, IDH2, SRSF2, ASXL1, NRAS, TET2 and TERT pro-
moter was done at diagnosis, leukemic transformation,
and after chemotherapy by DHPLC and Sanger’s Sequen-
cing. For details of experiments see Additional file 1 and
Additional file 2: Table S4.
Reverse transcription-polymerase chain reaction (RT-PCR)
and cloning of EWSR1-MYB
cDNA from each patient sample was amplified using
primers EWSR1_400F (5′-GCCCACTCAAGGATATGCA
C-3′) and MYB_561R (5′-TGCTTGGCAATAACAGAC
CA-3′), for the first amplification round; nested PCR was
set up with primers EWSR1_515F (5′-CAGACCGCC
TATGCAACTTC-3′) and MYB_433R (5′-GCACTGCAC
ATCTGTTCGAT-3′). PCR products were cloned and se-
quenced (Additional file 1).
Quantitative reverse transcription PCR (qRT-PCR) for MYB
and BCL2
MYB expression was investigated in our patient, at all
time points, and in 7 PMF cases (four at leukemic trans-
formation and three in paired chronic phase/leukemic
transformation) (TaqMan assay probe Hs00920556_m1;
Applied Biosystems, Foster City, CA). Negative controls
were four healthy BM samples. Positive controls were 12
acute leukemias with high MYB expression (4 RUNX1-
RUNX1T1 AML, 4 AML with MLL translocations, and
4 BCR-ABL1-positive B-cell ALL) [14]. Expression of
BCL2, a known MYB target, was also investigated in our
case (TaqMan assay probe Hs00608023_m1, Applied Bio-
systems). Amplifications were normalized to the endo-
genous reference control ABL1 (Hs00245445_m1, Applied
Biosystems) (Additional file 1).
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Fig. 1 (See legend on next page.)
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Results
Molecular cytogenetic and mutational analyses
Multi-FISH and whole chromosome paints showed
chromosome 22q11-q12 material inserted into chromo-
some 6q23 and revealed an additional rearrangement be-
tween der(22) and an apparently normal chromosome 9
(Fig. 1b) (Additional file 3: Figure S1). The breakpoint
occurred at 6q23 within the MYB oncogene (Additional
file 3: Figure S2). Fosmids for EWSR1 and the EWSR1-
MYB assay showed that the 5′EWSR1 was inserted into
the MYB locus (Fig.1c) (Additional file 3: Figure S2). The
EWSR1-MYB rearrangement was not detected at chronic
phase or in 3 consecutive samples analyzed after chemo-
therapy and during treatment with 5-AZA (Table 1).
SNPa detected a 96 Mb copy neutral loss of heterozygos-
ity (cnLOH) at 12q11-12q24.33 at chronic phase and
leukemic transformation. Lack of germinal material pre-
cluded definition as a congenital or acquired event. Apply-
ing a 50 Kb filter revealed a 99 kb loss at 22q11.1 (cytostart
17585764 - cytoend 17684472) only at leukemic transform-
ation (Fig. 1d) (Additional file 3: Figure S3). SRSF2
(c.284C >A; p.P95H) and TET2 (c.3781C >T; p.R1261C)
(c.2732_2733insC; p.A912Cfs*12) mutations were found,
and confirmed, at all disease stages (Table 1).
RT-PCR and qRT-PCR
At leukemic transformation an in-frame fusion tran-
script EWSR1-MYB with breakpoint in EWSR1 exon 7
(nt 927) (NM_013986.3) and MYB exon 2 (nt 223)
(NM_001130173.1) was detected. The 954 aminoacids pre-
dicted fusion protein retained the EWSR1 transcriptional-
activating domain (TAD) at the N-terminal and all MYB
functional domains at the C-terminal (Fig. 1e). After
chemotherapy, at hematological and cytogenetic remis-
sion, the EWSR1-MYB fusion disappeared. At leukemic
phase, MYB and BCL2 expression was respectively ≥4.7
and ≥2.8 fold higher than at remission. High MYB expres-
sion was detected in 7 PMF and in the 3 groups of acute
leukemia used as positive controls (Fig. 1f).
Discussion
This case of JAK2-positive PMF with very rapid evolution
to AML had a specific mutational profile at diagnosis
bearing mutations of JAK2, SRSF2 and TET2. A complex
rearrangement involving chromosomes 6, 9, and 22, which
produced a previously undescribed EWSR1-MYB fusion,
underlies the leukemic transformation.
EWSR1 is a member of the TET (TLS, EWSR1, TAFII68)
protein family which acts as multifunctional protein and
Table 1 Longitudinal cytogenetic and molecular studies in our patient with rapidly evolving PMF






Karyotype 46,XY [20] 46,XY,ins(6;22)(q23q11q12),del(22)(q11) [20] 46,XY [20] 46,XY [20] 46,XY [20]




yes yes yes n.d. n.d.
SRSF2 c.284C>A p.P95H yes yes yes n.d. n.d.
SNPa cnLOH 12q11-12q24.33 cnLOH: 12q11-12q24.33 n.d. n.d. n.d.
LOSS: 22q11.1
I-FISH: EWSR1-MYB negative positive negative negative negative
RT-PCR: EWSR1-MYB negative positive negative n.d. n.d.
n.d. not done
*from leukemia transformation
(See figure on previous page.)
Fig. 1 a) G-banded karyotype bone marrow cells at leukemic transformation showed ins(6;22)(q23.3;q11) and der(22q) (black arrows). b) Metaphase
FISH experiment with Whole Chromosome Paint (WCP) 6 (Texas Red) and WCP 22 (FITC). Genomic material of chromosome 22 was present on der(6)
and der(9) long arms. c) Schema of clones RP1-32B1 (MYB) (Spectrum Orange) and RP11-367E7 (EWSR1) (Spectrum Green) and their mapping. Normal
and derivative chromosomes 6 and 22 hybridization patterns; a green/orange fusion signal was present on der(6). A fusion signal was
found in interphase nuclei (yellow arrow). d) SNPa analysis detected loss at 22q (red triangle) in BM sample at leukemic transformation.
e) Schema of the EWSR1-MYB fusion gene and putative protein. f) MYB expression analysis in four combined cases at chronic phase and
leukemic transformation and in a positive control group (4 RUNX1-RUNX1T1 AML, 4 MLL-positive AML, and 4 BCR-ABL1-positive B-cell ALL). g) Longitudinal
expression of MYB and BCL2 in the index case. Data are reported for one representative of three independent experiments. Abbreviations: der, derivative
chromosome; nl, normal; TAD, transcriptional-activating domain; R1, R2, R3, imperfect aminoacidic repeats; NRD, negative regulatory domain; CP, chronic
phase; LT, leukemic transformation; wt, wild-type; R, relapse
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regulates transcription and mRNA splicing to maintain cel-
lular homeostasis. Although well known in soft tissue sar-
coma, EWSR1 fusions have only occasionally been detected
in leukemia [15–19]. Interestingly, all EWSR1 fusions
retained the TAD portion at the N-terminal and the partner
DNA Binding Domain (DBD) at the C-terminal. Since
EWSR1-FLI1, the most frequent sarcoma-associated fusion,
acted as an aberrant transcription factor, deregulating
several targets [20], one might speculate that the EWSR1-
MYB fusion in our patient also acted as an aberrant tran-
scription factor, altering theMYB transcriptional program.
MYB is a leucin zipper transcription factor which plays a
key role in cell proliferation and differentiation [21–23].
High level of MYB is common in AML associated with
BCR-ABL1, RUNX1-RUNX1T1, MYST3-CREBBP, or MLL-
rearrangements [11, 12, 24]. Chromosomal aberrations pla-
cing MYB under the promoter of a partner gene, such as
TCRB-MYB in T-cell ALL [14, 25] or in close proximity of
super-enhancer regions, such as MYB-NFIB in adenoid
cystic carcinoma [26], caused MYB over-expression. It is
worth noting, however, that besides promoting tumour
growth through MYB over-expression, the MYB fusions
might have their own oncogenic potential as demonstrated
for the MYB-QKI in pediatric angiocentric glioma, which
drives tumor development in vitro and in vivo models [27].
High MYB level confers self-renewal properties on
leukemic cells and blocks differentiation, thus it has
been regarded as a putative therapeutic target [11, 12].
Indeed, in vitro and in vivo studies showed that a slight
MYB drop is enough to block leukemic cell proliferation
without affecting normal haematopoiesis [28]. The
present study confirmed two previous reports of high
MYB expression in PMF [29, 30] as it was detected in all
cases at chronic phase with a rising trend at leukemic
transformation (Fig. 1f ).
In determining whether and how the aberrant EWSR1-
MYB transcription factor played a role in rapid disease
progression, paired longitudinal studies showed that the
EWSR1-MYB fusion was closely linked to leukemic trans-
formation, as it was not detected at diagnosis and disap-
peared after treatment. As a functional consequence of
MYB deregulation we investigated BCL2 expression as it is
a well-known MYB target which acts as an anti-apoptotic
onco-suppressor. Recent findings in leukemia xenograft
models showed that sustained MYB expression main-
tained high BCL2 expression and consequently, inhib-
ited leukemic cell death [10]. In line with these data, we
found that MYB as well as BCL2 expression was higher at
leukemic transformation than after treatment (Fig. 1g).
Our patient responded to treatment by regressing
from AML to PMF maintaining JAK2, TET2 and SRSF2
mutations. Therefore, the JAK2-positive clone, showed a
constant allele burden in all disease phases, marking the
PMF stem line which persisted throughout disease, while
the EWSR1-MYB fusion was the hallmark of the leukemic
clone. Whether EWSR1-MYB affected a JAK2V617F cell or
developed as an independent clone, could not be estab-
lished. Interestingly Engle E.K. et al. [31], identified MYB
mutations in a complex PMF subclonal branching.
Conclusion
We report a unique case of JAK2V617F PMF. Rapid leukemia
transformation, due to complex cytogenetic rearrangement,
produced a previously undescribed EWSR1-MYB fusion
that appeared to act as an aberrant transcription factor de-
regulating BCL2. Our study provided new insights to
point to MYB as a good molecular target in patients pre-
senting with high-risk PMF [11, 32].
Additional files
Additional file 1: Detailed materials/methods and results. (DOC 68 kb)
Additional file 2: Table S1. FISH clones for chromosome 6 long arm
breakpoint characterization. Table S2. FISH clones for chromosome 22
long arm telomeric breakpoint characterization. Table S3. FISH clones for
chromosome 9 long arm breakpoint characterization. Table S4. Genes,
amplicons and primers for mutational analysis. (DOC 991 kb)
Additional file 3: Figure S1. Multi-FISH analysis showed a complex
rearrangement between chromosomes 6, 9 and 22 (yellow arrows).
Figure S2. A) Chromosome 6q23 breakpoint within MYB. B) Chromosome
22q11.2 breakpoint within EWSR1. Figure S3. A) SNPa findings at PMF
diagnosis: no CNV with 100 and 50 Kb filters (left panel) but LOH at 12q
(right panel, black arrow). B) SNPa findings at leukemic transformation: a
genomic loss, at 22q11.2, was identified with a 50 Kb filter (left panel, red
arrow); LOH at 12q (right panel, red arrow). (DOC 3447 kb)
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